Individuals living with type 2 diabetes (T2D) had a significantly lower risk of poor cardiovascular health when they used a GLP-1 receptor agonist (GLP-1 RA) in combination with adhering to healthy ...

On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026Continues to advance broad late-stage pipeline, with five ongoing Phase 3 ...

The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...

In that context, the rise of two-fastball arsenals offers a compelling alternative. By pairing shapes — sinkers for ...

GMRx2 is an innovative single pill combination of three medicines designed to deliver the blood pressure-lowering benefits of triple combination therapy early in the treatment pathway, supported by an ...

Madrigal has made three in-licensing deals since July 2025, picking up multiple potential MASH therapeutics. Read why MDGL ...

Stacker reports the 2026 states ranked lowest in livability, highlighting issues like poor education, health, and high crime in Alabama, West Virginia, and others.

Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41st Asia-Pacific Academy of ...

A newly released educational resource provides a detailed, research-informed examination of “ TMS and ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination ...

A study in BMC Anesthesiology finds combining anesthetic approaches in ACLr improves recovery and decreases complications.

A low-dose, single-pill combination proved to be as effective as — and in some cases, superior to — standard-dose monotherapy ...